AR074402A1 -
HUMAN CORIONIC GONADOTROPHINE (HCG): ITS ASSOCIATION WITH CYCLODEXTRINE AND ITS CLINICAL APPLICATION IN THE REDUCTION OF GLUCEMIA AND PLASMATIC LEPTINE
- Google Patents
HUMAN CORIONIC GONADOTROPHINE (HCG): ITS ASSOCIATION WITH CYCLODEXTRINE AND ITS CLINICAL APPLICATION IN THE REDUCTION OF GLUCEMIA AND PLASMATIC LEPTINE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Belluscio Daniel OscarfiledCriticalBelluscio Daniel Oscar
Priority to ARP090104541priorityCriticalpatent/AR074402A1/en
Publication of AR074402A1publicationCriticalpatent/AR074402A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Uso de la hCG como agente regulador de las lectinas, así como también de la glucemia plasmática. Reivindicación 1: Un compuesto de Gonadotrofina Coriónica (hCG)/ciclodextrina caracterizada por incluir mas de 8 mg/ml ciclodextrina por cada 300 UI de hCG.Use of hCG as a lectin regulating agent, as well as plasma glycemia. Claim 1: A Chorionic Gonadotrophin (hCG) / cyclodextrin compound characterized by including more than 8 mg / ml cyclodextrin for every 300 IU of hCG.
ARP0901045412009-11-252009-11-25
HUMAN CORIONIC GONADOTROPHINE (HCG): ITS ASSOCIATION WITH CYCLODEXTRINE AND ITS CLINICAL APPLICATION IN THE REDUCTION OF GLUCEMIA AND PLASMATIC LEPTINE
AR074402A1
(en)
HUMAN CORIONIC GONADOTROPHINE (HCG): ITS ASSOCIATION WITH CYCLODEXTRINE AND ITS CLINICAL APPLICATION IN THE REDUCTION OF GLUCEMIA AND PLASMATIC LEPTINE
HUMAN CORIONIC GONADOTROPHINE (HCG): ITS ASSOCIATION WITH CYCLODEXTRINE AND ITS CLINICAL APPLICATION IN THE REDUCTION OF GLUCEMIA AND PLASMATIC LEPTINE
HUMAN CORIONIC GONADOTROPHINE (HCG): ITS ASSOCIATION WITH CYCLODEXTRINE AND ITS CLINICAL APPLICATION IN THE REDUCTION OF GLUCEMIA AND PLASMATIC LEPTINE
An aqueous composition containing bromhexine, wherein the composition has an amount of sugar-alcohols less than 10 g based on 100 ml of the composition; and its use for secretory therapy in acute and chronic bronchopulmonary diseases.
modified peptide, salt of a modified peptide, medicament, and methods for treating or alleviating cardiovascular disease and for producing a modified peptide
BIOPOLIMERIC COMPOSITION FOR THE ENCAPSULATION OF CELLS, METHOD OF PRODUCTION OF A BIOPOLIMERIC COMPOSITION FOR THE ENCAPSULATION OF CELLS, METHOD TO PROMOTE THE CYTOPROTECTION OF CELLS AND USE OF A BIOPOLIMERIC COMPOSITION FOR THE ENCLOSURE
HUMAN CORIONIC GONADOTROPHINE (HCG): ITS ASSOCIATION WITH CYCLODEXTRINE AND ITS CLINICAL APPLICATION IN THE REDUCTION OF GLUCEMIA AND PLASMATIC LEPTINE
Sustained-release parenteral pharmaceutical suspension formulation comprising estradiol and progesterone microparticles together with a surfactant, an isosmotic agent, a viscous agent and one or more preservatives, useful in hormone replacement therapy in female mammals.